{"nctId":"NCT02663453","briefTitle":"Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition","startDateStruct":{"date":"2013-12"},"conditions":["Cholestasis"],"count":44,"armGroups":[{"label":"study group","type":"EXPERIMENTAL","interventionNames":["Drug: multicomponent lipid emulsion"]},{"label":"control group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: pure soybean oil lipid emulsion"]}],"interventions":[{"name":"multicomponent lipid emulsion","otherNames":["SMOF lipid"]},{"name":"pure soybean oil lipid emulsion","otherNames":["Intralipid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inborn infants with a gestational age of less than 30 weeks\n* Who required parenteral nutrition for at least 7 days\n\nExclusion Criteria:\n\n* Evidence of congenital infection\n* Perinatal asphyxia\n* Congenital anomalies\n* Severe IVH\n* Thrombocytopenia\n* Shock or circulation failure\n* Renal or hepatic disorders.","healthyVolunteers":false,"sex":"ALL","minimumAge":"24 Weeks","maximumAge":"30 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Neonatal Cholestasis","description":"direct bilirubin level of more than 2 mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Neonatal Morbidities","description":"retinopathy of prematurity, bronchopulmonary dysplasia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Extrauterine Growth Restriction (EUGR)","description":"weight that is less than the tenth percentile for corrected gestational age by the time of discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight Gain","description":"in-hospital weight gain at birth until discharge (gram/day)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"3.9"},{"groupId":"OG001","value":"18.8","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"Height Gain","description":"in-hospital height gain at birth until discharge (cm/week)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.2"},{"groupId":"OG001","value":"0.8","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Head Circumference Gain","description":"in-hospital head circumference gain at birth until discharge (cm/week)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.2"},{"groupId":"OG001","value":"0.7","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Assessment of Gamma Glutamyltranspeptidase (GGT)","description":"blood samples were obtained before enrollment, week 1, 2 and 3 (U/L) after parenteral nutrition administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134.7","spread":"113.8"},{"groupId":"OG001","value":"138.7","spread":"62.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":"58.8"},{"groupId":"OG001","value":"79.5","spread":"45.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":"47.5"},{"groupId":"OG001","value":"68.6","spread":"43.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":"68.3"},{"groupId":"OG001","value":"95.4","spread":"85.2"}]}]}]},{"type":"SECONDARY","title":"Assessment of Alanine Aminotransferase (ALT)","description":"blood samples were obtained before enrollment, week 1, 2 and 3 (U/L) after parenteral nutrition administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"12.8"},{"groupId":"OG001","value":"15.1","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"7.8"},{"groupId":"OG001","value":"15.1","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":"8.7"},{"groupId":"OG001","value":"19.8","spread":"13.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":"6.8"},{"groupId":"OG001","value":"17.7","spread":"7.9"}]}]}]},{"type":"SECONDARY","title":"Assessment of Aspartate Aminotransferase (AST)","description":"blood samples were obtained before enrollment, week 1, 2 and 3 (U/L) after parenteral nutrition administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":"21.6"},{"groupId":"OG001","value":"55.6","spread":"28.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":"22.0"},{"groupId":"OG001","value":"26.0","spread":"9.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":"8.0"},{"groupId":"OG001","value":"24.4","spread":"6.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"3.7"},{"groupId":"OG001","value":"25.9","spread":"8.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":[]}}}